Abeona Therapeutics Inc. (NASDAQ:ABEO) shares saw strong trading volume on Tuesday . 92,251 shares traded hands during trading, an increase of 51% from the previous session’s volume of 61,004 shares.The stock last traded at $2.89 and had previously closed at $2.82.

Several research analysts have recently issued reports on the company. Maxim Group reaffirmed a “buy” rating and set a $6.00 price target on shares of Abeona Therapeutics in a research note on Tuesday. Zacks Investment Research raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 20th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Abeona Therapeutics in a research note on Wednesday, June 22nd.

The firm’s 50-day moving average is $2.56 and its 200 day moving average is $2.64. The stock’s market capitalization is $97.73 million.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.04. On average, analysts expect that Abeona Therapeutics Inc. will post ($0.59) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Abeona Therapeutics stock. Royce & Associates LLC raised its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned approximately 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent SEC filing.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.